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NOTABLENOTES
Tungiasis
“The Greatest Curse That Has Ever Afflicted Africa”
Fabrizio Vaira, MD; Gianluca Nazzaro, MD; Stefano Veraldi, MD
Because of air travel, diseases formerly restricted to tropical and sub-
tropical areasmayalsonowbeobserved incountrieswith temperate cli-
mates. Among these diseases, one often underrecognized byWestern
dermatologists is tungiasis, an infestation caused by penetration in the
skin of the gravid female of the flea Tunga penetrans.1,2 This infestation
occurs in poor communities in South America and Africa and sporadi-
cally affects travelers toendemic areas.Medical entomologyclaims that
the South American continent was its original site.
Thehistoryof this insidious flea ischaracterizedbycuriousanecdotes.
The first reports dateback to thepre-Incanperiod: artists of theMoringa
and Chimu cultures depicted morphological features of T penetrans on
ceramic jars. The first contact with Europeans was after the Christopher
Columbus’ssailors landed inHaiti.Theyfoughtagainst thisparasiteaswell
as against thenativesuntil theywere “slaughtered”byboth. Soon, tungi-
asisbecameavery importantproblemfor thecolonizingEuropeantroops
whohad no previous experiencewith this flea. For instance, the Spanish
military expedition in Colombia (1538), led byGonzalo Ximenez deQue-
sada,wasstoppedfora longperiod inSororoca, a town infestedbyTpen-
etrans. These soldiers suffered so severely that the walking was very
difficult.1NativewomenhadcompassionandshowedtheSpaniardshow
toremovethe imbeddedfleas.Theseancientmethodsofextractionofthe
fleas fromtheskinarestill used insomeareas inSouthAmericaandAfrica.
ThefirstscientificdescriptionofTpenetransandtungiasiswasprovided
byAleixodeAbreuin1623.2Tungapenetrans isoneofthefewparasitesthat
spreadfromtheWesterntotheEasternhemisphere.Accordingtothetra-
dition, the British ship Thomas Mitchell, during its 1872-1873 voyage,1,2
broughtthefleafromBrazil toAngola inbagsofsandusedasballast.Tunga
penetrans spread rapidly along theAfricanWest Coasts and sub-Saharan
regions followingthetradingcaravans.1Thesmall fleabroughtAfrica to its
knees. Indeed, towns and villages were so infested that inhabitants
were often forced to leave them. Even though T penetransdid not cause
death, it causedpainful lesionsonthefeet thatpreventedwalking.There-
fore, people starved because they were unable to work in fields. Lionel
Decle, at the endof the 19th century,wrote: “In this village therewasnot
manorwomanwhowasnot coveredwithulcers...myexperiencemakes
me look upon the jigger as the greatest curse that has ever afflicted
Africa.”3(p571)
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